Progress in research on tumor-targeted superantigens

Immunotherapy is a hot and future trend in the field of cancer researchIn the process of tumor immunotherapy, the targetspecificness of the drug to tumor tissue and the effectiveness of the drug in activating the immune system in the tumor microenvironment are the key to the success of treatmentSuper antigen molecules can effectively activate the human immune response at very low doses, and produce effective immune killing of tumor cells and solid tumors, is a very promisingtumorimmunotherapy agentthe Microbial Resources and Ecology Group of Shenyang Institute of Applied Ecology of the Chinese Academy of Sciences, relying on the key laboratory of super antigen research in Shenyang, is committed to the research, structural transformation and development of immuno-anti-tumor drugs in the super antigen biomolecular effect relationshipRecently, Xu Mingxuan, a researcher at Shenyang Institute of Ecology, innovatively combined the tumor-targeted membrane peptide iRGD with the active-enhanced super antigen modifier ST-4 in a genetically engineered way to build a new tumor-targeted super antigen ST-4-iRGDThe study selected 4T1breast cancercell line and B16F10melanomacell line, respectively, in the in vitro cell model and the in-body cell model of the lotus tumor, respectively, the tumor targeting and anti-tumor activity of ST-4-iRGD were systematically evaluatedThe study found that ST-4-iRGD can target and penetrate tumor-specifically into tumor tissue, and showsignificantly enhanced tumor inhibition, solid tumor smaller, and significantly prolonged survivalAt the same time, the study found that the introduction of targeted molecules significantly strengthened the tissue distribution of super antigens in the tumor microenvironment, effectively increased the degree of immersion of lymphocytes in solid tumor tissue, and played a strongertumorimmunotherapy effect In addition, no toxic effects caused by ST-4-iRGD were found throughout the study, and have the prospect of new drug development the results were published in the pharmaceutical top international journal Top International Journal of Pharmacy in 2020 under the title of An iRGD peptide fused superantigen mutant ei dydd tumor-targeting and T lymphocyte lyingyn in cancerthed ei dingydd (
Bio valley Bioon.com) .